Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 24, 2022
Reporting Period: Event-based report regarding a material definitive agreement entered into on January 24, 2022.
Key Financial Metrics
This filing reports on a specific corporate transaction rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, margins, and debt levels for a reporting period are not provided in this document.
Transaction Financial Terms:
- Upfront Payment: $30.0 million.
- Potential Milestone Payments: Up to $705.0 million (contingent on development and sales).
- Revenue Share: Capricor will receive a meaningful, double-digit share of product revenue from sales to the partner.
Material Changes
The primary material change is the entry into an Exclusive Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd. on January 24, 2022.
- Product: CAP-1002, the Company's lead product candidate for the treatment of Duchenne muscular dystrophy.
- Role Allocation: Nippon Shinyaku is appointed as the exclusive distributor in the United States. Capricor retains responsibility for the HOPE-3 clinical trial and manufacturing of CAP-1002.
- Commercial Model: Capricor will sell commercial product to Nippon Shinyaku rather than distributing directly in the U.S. market.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to file the full Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2021. Certain terms and provisions are expected to be filed under confidential treatment.
Risks and Contingencies:
- Milestone Contingency: The potential $705.0 million in additional payments is not guaranteed and depends on achieving specific development and sales milestones.
- Regulatory/Confidentiality: Full details of the agreement are not currently public due to confidential treatment requests.
Investor Verification Checklist
- Verify the specific "double-digit" revenue share percentage once the full agreement is filed in the Form 10-K.
- Confirm the specific triggers and timelines for the $705.0 million in potential milestone payments.
- Monitor the status of the HOPE-3 clinical trial, as Capricor retains responsibility for its conduct.
- Review the Form 10-K for the year ended December 31, 2021, for the complete text of the agreement and any confidential terms.